ArticleClinical ophthalmology (Auckland, N.Z.)2025
Treat and Extend Regimen of Aflibercept in the Treatment of Type 1 Choroidal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy: Three-year Follow-Up.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report three-year treatment results of intravitreal aflibercept using a treat-and-extend (TAE) regimen for type 1 choroidal neovascularization (CNV) in chronic central serous chorioretinopathy (CSC). Patients and Methods: This prospective, single-center interventional study completed 34 patients (34 eyes) (16 patients previously treated by photodynamic therapy (PDT) and 18 naive patients) treated with 2.0 mg intravitreal aflibercept. All patients received 3 initial loading intravitreal injections every 4 weeks, followed by a TAE protocol. The primary outcome was decimal best-corrected visual acuity (BCVA) at year 3. Results: Overall, mean decimal BCVA increased significantly from 0.44 (SD; 0.35) at baseline to 0.59 (SD; 0.31) at the final visit (p˂0.001). At year 3, mean decimal BCVA in the PDT-treated group compared to the naive group was statistically different, 0.48 (SD; 0.29) vs 0.71 (SD; 0.31), respectively (p=0.04). Overall, complete resolution of fluid was noted in 73% at 3 years. Complete resolution of fluid in the PDT-treated group and the naive group was 56% and 89% (p=0.01), respectively. The total mean number of aflibercept injections was 18.0 (SD; 5.6). Mean number of injections was 20.1 (SD; 5.3) in the PDT-treated group and 15.9 (SD; 5.8) in the naive group (p=0.03). Conclusion: Intravitreal aflibercept using a TAE regimen improved visual and anatomical outcomes of patients with type 1 CNV secondary to chronic CSC in long-term follow-up. Naive patients had a better visual outcome and a higher incidence of complete fluid resolution than PDT-treated patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.